The CEO and CFO of rare disease drugmaker Alexion just left the company (ALXN)

Wikimedia Commons

Two top executives at Alexion Pharmaceuticals have left the company.

Alexion, a company that makes treatments for rare diseases, said on Monday that Chief Executive David Hallal had resigned, effective immediately, and named board member David Brennan as interim CEO.

The company also said Chief Financial Officer Vikas Sinha left to pursue other opportunities, effective immediately, and would be succeeded by David Anderson, who was earlier CFO at Honeywell International Inc.

The departures come at a moment of “great corporate strength and momentum,” Alexion chairman Dr. Leonard Bell said in a call Monday. The company has not released its third-quarter 10-Q. The company said it expects to file that by January 2017. 

Alexion had disclosed last month that it was investigating allegations made by a former employee regarding sales practices involving its flagship and costly blood disorder drug Soliris.

The company said on Monday the investigation had not identified any facts that require Alexion to update its previously reported historical results at this point in time.

Wikimedia Commons

(Reuters reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)

NOW WATCH: Here's what fruits and vegetables looked like before we domesticated them